Reimbursement Decisions for Pharmaceuticals in Sweden: the Impact of Cost-Effectiveness and Disease Severity

Abstract

All the estimated ICER values were higher than the thresholds usually described in the literature (€ 20,000-30,000/QALY), with relevant differences among the groups. In both scenarios, payers were less prone to pay for therapeutic improvements compared to the rest of the participants. On the other hand, oncologists were the ones that most valued gains in survival for a new treatment while patients assigned a higher value for money to a treatment that enhanced the quality of life. QA4 ReimbuRsement Decisions foR PhARmAceuticAls in sweDen: the imPAct of cost-effectiveness AnD DiseAse seveRity